Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07437560
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo (MTII-VIT)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Melanotan II (Synthetic Cyclic Melanocortin Receptor Agonist) as an Adjunct to Narrowband UV-B Phototherapy in Adults With Stable Nonsegmental Vitiligo
Sponsor: Hudson Biotech
Interventions
Melanotan II (MT-II) Narrowband UV-B (NB-UVB) phototherapy Placebo
Updated 1 time since 2026 Last updated: Feb 22, 2026 Started: Feb 2, 2026 Primary completion: Feb 14, 2027 Completion: Feb 17, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07437560, this PHASE2 trial focuses on NonSegmental Vitiligo and Nonsegmental Vitiligo (Stable) and remains actively recruiting participants. Sponsored by Hudson Biotech, it has been updated 1 time since 2026, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Hudson Biotech
Data source: Hudson Biotech
For direct contact, visit the study record on ClinicalTrials.gov .